House Seeks FDA Reports on Pharmacy Tied to Meningitis

Lawmakers probing the U.S. meningitis outbreak are focusing on why the pharmacy linked to this year’s infections didn’t receive greater scrutiny when potential regulatory violations were found six years ago.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.